ESTRO Brachytherapy for Prostate Cancer 2018

Pathohistology after SRP correlates to type of RT ?!

EBRT

Temporary BT Permanent BT

p

n

30

22

66

0.02

pT2a-c

20(66.7%)

11(50%)

54(81.8%)

0.001*

pT3a-b

10(33.3%)

11(50%)

12(18.2%)

0.001*

pN1

5(16.6%)

7(32%)

4(6.1%)

0.001*

SM+

4(13.3%)

4(18.2%)

4(6.1%)

0.001*

*p for comparison permanent BT vs EBRT/temporary BT

Heidenreich et al ESTRO 2012